This case study details the successful acceleration of drug development for a small biotech company, focusing on overcoming significant challenges to achieve First-in-Human (FIH) dosing for a promising oncology asset. Faced with a highly competitive market and ambitious objectives - to complete the pre-Investigational New Drug (IND) submission 50% faster than industry standard (within 6 months) and administer the first dose within 15 days of IND clearance - the project encountered obstacles such as team complexity, lack of clarity in roles and responsibilities, stakeholder misalignment, and inefficient systems.
The strategic approach involved establishing clear leadership directives, setting unambiguous expectations for roles and communication, fostering team collaboration, and deploying robust team infrastructure. This enabled cross-functional alignment, removed decision bottlenecks, and empowered rapid execution.
As a result, the team achieved remarkable milestones: submitting the P-IND letter package and IND modules 50% faster than industry standards and administering the first dose to the first subject within an unprecedented 24 hours of IND clearance. The case study highlights the critical role of strong leadership, strategic coordination, efficiency, and data integrity in accelerating complex drug development timelines while maintaining quality and driving regulatory success.
If you want to know more about this success story, kindly click the button below to schedule a call
